All’s well with avel.

As opposed to almost everything else in life, this has been a peach of a year for the anti-PD-L1 agent avelumab, further bolstered by official results of JAVELIN Bladder 100 reported in abstract form. 700 patients with unresectable urothelial carcinoma not progressing after first-line gem + platinum chemo were randomized to +/- maintenance avelumab. As easily predicted based on PR releases, the primary endpoint of overall survival was significantly prolonged across the board from a median of 14 → 21 months. This held true even for the half of enrollees without PD-L1(+) tumors. TBL: Adding maintenance avelumab to unresectable chemo-responsive urothelial cancer dramatically improves survival. | Powles, ASCO 2020